- Home
- MDIA vs NSPR Comparison
MDIA vs NSPR Comparison
Compare MDIA & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDIA
- NSPR
- Stock Information
- Founded
- MDIA 2019
- NSPR 2005
- Country
- MDIA United States
- NSPR Israel
- Employees
- MDIA N/A
- NSPR N/A
- Industry
- MDIA Broadcasting
- NSPR Medical/Dental Instruments
- Sector
- MDIA Consumer Discretionary
- NSPR Health Care
- Exchange
- MDIA Nasdaq
- NSPR Nasdaq
- Market Cap
- MDIA 61.4M
- NSPR 63.0M
- IPO Year
- MDIA N/A
- NSPR N/A
- Fundamental
- Price
- MDIA $1.08
- NSPR $2.72
- Analyst Decision
- MDIA
- NSPR Strong Buy
- Analyst Count
- MDIA 0
- NSPR 2
- Target Price
- MDIA N/A
- NSPR $4.75
- AVG Volume (30 Days)
- MDIA 312.4K
- NSPR 27.8K
- Earning Date
- MDIA 11-14-2024
- NSPR 03-05-2025
- Dividend Yield
- MDIA N/A
- NSPR N/A
- EPS Growth
- MDIA N/A
- NSPR N/A
- EPS
- MDIA N/A
- NSPR N/A
- Revenue
- MDIA $69,296,000.00
- NSPR $6,821,000.00
- Revenue This Year
- MDIA N/A
- NSPR $13.36
- Revenue Next Year
- MDIA N/A
- NSPR $49.64
- P/E Ratio
- MDIA N/A
- NSPR N/A
- Revenue Growth
- MDIA 94.96
- NSPR 24.70
- 52 Week Low
- MDIA $0.40
- NSPR $1.81
- 52 Week High
- MDIA $6.86
- NSPR $3.42
- Technical
- Relative Strength Index (RSI)
- MDIA 42.53
- NSPR 47.01
- Support Level
- MDIA $1.00
- NSPR $2.50
- Resistance Level
- MDIA $1.16
- NSPR $2.83
- Average True Range (ATR)
- MDIA 0.12
- NSPR 0.20
- MACD
- MDIA -0.00
- NSPR -0.01
- Stochastic Oscillator
- MDIA 48.48
- NSPR 41.54
About MDIA Mediaco Holding Inc.
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales and events including sponsorships and ticket sales, licensing, and syndication.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.